Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma

News
Video

Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Related Videos
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Elias Jabbour, MD
Marc J. Braunstein, MD, PhD
Related Content
Harout Semerjian, CEO of GlycoMimetics

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Rebecca Klisovic, MD, of University Hospitals Seidman Cancer Center

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
Angelos Stergiou, MD, ScD hc

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

May 1st 2024
Article
FDA

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024
Article